ES2196898T3 - Antagonistas de receptores de crf y metodos relacionados. - Google Patents

Antagonistas de receptores de crf y metodos relacionados.

Info

Publication number
ES2196898T3
ES2196898T3 ES99961675T ES99961675T ES2196898T3 ES 2196898 T3 ES2196898 T3 ES 2196898T3 ES 99961675 T ES99961675 T ES 99961675T ES 99961675 T ES99961675 T ES 99961675T ES 2196898 T3 ES2196898 T3 ES 2196898T3
Authority
ES
Spain
Prior art keywords
crf receptor
receptor antagonists
crf
antagonists
receivers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99961675T
Other languages
English (en)
Spanish (es)
Inventor
Mustapha Haddach
Zhiqiang Guo
James R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ES2196898T3 publication Critical patent/ES2196898T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES99961675T 1998-11-12 1999-11-12 Antagonistas de receptores de crf y metodos relacionados. Expired - Lifetime ES2196898T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19095898A 1998-11-12 1998-11-12
US40074499A 1999-09-21 1999-09-21

Publications (1)

Publication Number Publication Date
ES2196898T3 true ES2196898T3 (es) 2003-12-16

Family

ID=26886600

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99961675T Expired - Lifetime ES2196898T3 (es) 1998-11-12 1999-11-12 Antagonistas de receptores de crf y metodos relacionados.

Country Status (19)

Country Link
US (3) US6348466B1 (enExample)
EP (1) EP1129096B1 (enExample)
JP (1) JP2002529469A (enExample)
KR (1) KR20010080402A (enExample)
CN (1) CN1178941C (enExample)
AT (1) ATE240958T1 (enExample)
AU (1) AU755997B2 (enExample)
BR (1) BR9915129A (enExample)
CA (1) CA2349904A1 (enExample)
DE (1) DE69908173T2 (enExample)
DK (1) DK1129096T3 (enExample)
ES (1) ES2196898T3 (enExample)
HK (1) HK1038925B (enExample)
IL (1) IL143105A0 (enExample)
NO (1) NO20012228D0 (enExample)
NZ (1) NZ511267A (enExample)
PT (1) PT1129096E (enExample)
TR (1) TR200102178T2 (enExample)
WO (1) WO2000027850A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
AU2001255673A1 (en) * 2000-05-01 2001-11-12 Dupont Pharmaceuticals Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
JP2003533526A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関連する方法
US6541469B2 (en) 2000-05-18 2003-04-01 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6747034B2 (en) * 2000-11-03 2004-06-08 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1354884B1 (en) 2000-12-28 2007-10-10 Ono Pharmaceutical Co., Ltd. Cyclopenta[d]pyrazolo[1,5-a]pyrimidine compound as crf receptor antagonist
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE320254T1 (de) * 2001-04-30 2006-04-15 Glaxo Group Ltd Crf receptor antagonisten
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
DE602004028820D1 (de) 2003-06-25 2010-10-07 Ono Pharmaceutical Co Methansulfonsäuresalz einer pyrazolopyrimidinverbindung, kristall davon und verfahren zu deren herstellung
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
JP2007515473A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
CN101133157A (zh) 2004-06-03 2008-02-27 阿什洛米克斯控股有限公司 诊断应激的药物和方法
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ES2380951T3 (es) 2005-05-05 2012-05-21 Ardea Biosciences, Inc. Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
US7595324B2 (en) 2006-11-09 2009-09-29 Ardea Biosciences, Inc. Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
MX2010005776A (es) 2007-11-27 2010-08-31 Ardea Biosciences Inc Nuevos compuestos y composiciones y metodos de uso.
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
CA2150483C (en) 1992-12-17 1999-09-14 Pfizer Limited Pyrazoles and pyrazolopyrimidines
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
HU219911B (hu) 1994-06-16 2001-09-28 Pfizer Inc. Pirazolo-piridin-származékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
AU716993B2 (en) 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
AU709203B2 (en) 1996-08-06 1999-08-26 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
BR9711970A (pt) * 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands

Also Published As

Publication number Publication date
AU755997B2 (en) 2003-01-02
DE69908173D1 (de) 2003-06-26
CA2349904A1 (en) 2000-05-18
NO20012228L (no) 2001-05-04
CN1326458A (zh) 2001-12-12
EP1129096B1 (en) 2003-05-21
WO2000027850A3 (en) 2000-08-03
WO2000027850A2 (en) 2000-05-18
DE69908173T2 (de) 2004-08-19
CN1178941C (zh) 2004-12-08
US6723721B2 (en) 2004-04-20
NZ511267A (en) 2002-12-20
US20020143008A1 (en) 2002-10-03
HK1038925A1 (en) 2002-04-04
NO20012228D0 (no) 2001-05-04
HK1038925B (en) 2003-12-05
ATE240958T1 (de) 2003-06-15
DK1129096T3 (da) 2003-09-15
KR20010080402A (ko) 2001-08-22
IL143105A0 (en) 2002-04-21
EP1129096A2 (en) 2001-09-05
US20040229879A1 (en) 2004-11-18
AU1819900A (en) 2000-05-29
US6348466B1 (en) 2002-02-19
BR9915129A (pt) 2001-08-07
PT1129096E (pt) 2003-09-30
TR200102178T2 (tr) 2002-01-21
JP2002529469A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
ES2196898T3 (es) Antagonistas de receptores de crf y metodos relacionados.
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
DE60231911D1 (de) Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
PT1326643E (pt) Inibicao do efeito emetico da metformina com antagonistas de receptores 5-ht3
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY26130A1 (es) Compuestos para tratar la obesidad
PA8486001A1 (es) Composiciones de celecoxib
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
BR0015605A (pt) Composição e uso
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
TR199900326T2 (xx) �st solunum yollar� alerjik tepkisinin histamin resept�r antagonistlerin bir birle�imi ile tedavisi.
DE60039921D1 (de) Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
DE60041763D1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2095662T3 (es) Derivados de imidazol con actividad antagonista de la angiotensina ii.